Vetr cut shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a sell rating to a strong sell rating in a research report released on Tuesday. They currently have $12.46 target price on the specialty pharmaceutical company’s stock.
A number of other equities analysts have also recently commented on the company. Stifel Nicolaus restated a buy rating and set a $35.00 target price (down from $45.00) on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 17th. Deutsche Bank AG set a $18.00 price target on Valeant Pharmaceuticals International and gave the company a hold rating in a research report on Friday, May 19th. Royal Bank Of Canada set a $19.00 price target on Valeant Pharmaceuticals International and gave the company a sector perform rating in a research report on Monday, June 19th. Zacks Investment Research lowered Valeant Pharmaceuticals International from a hold rating to a strong sell rating in a research report on Thursday, July 13th. Finally, Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research report on Sunday, July 30th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $17.62.
Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at 13.99 on Tuesday. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $27.84. The company’s market capitalization is $4.88 billion. The company has a 50 day moving average price of $14.48 and a 200 day moving average price of $13.21.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to analysts’ expectations of $2.23 billion. During the same period last year, the business posted ($0.88) EPS. Valeant Pharmaceuticals International’s revenue for the quarter was down 7.7% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/valeant-pharmaceuticals-international-inc-vrx-downgraded-by-vetr-inc.html.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were purchased at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.87% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. Gruss & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International in the first quarter worth $104,000. Harbor Advisors LLC acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at $110,000. WMS Partners LLC acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at $116,000. PNC Financial Services Group Inc. increased its stake in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at $127,000. 50.49% of the stock is owned by hedge funds and other institutional investors.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.